Abstract:Pure pentachloronitrobenzene (PCNB) is a colorless crystalline solid (Worthing, 1983). The commercial product may have a light- yellow to cream color with a musty odor (Hartley and Kidd, 1983). It is practically insoluble in a number of organic solvents. The compound is reasonably stable but may undergo hydrolysis in a strong alkaline medium (Hartley and Kidd, 1983). In 1983, Olin Corp., Leland, MS, was the only manufacturer of PCNB in the United States (SRI, 1984; Hartley and Kidd, 1983). No data for U.S. production volume for this chemical are available, but recent production source data (USITC, 1985; SRI, 1985) suggest that this chemical is no longer commercially produced in the United States. The primary usage of PCNB is as a soil fungicide for a wide variety of crops and in seed treatment (Worthing, 1983; Hartley and Kidd, 1983). The fate of PCNB in water has not been comprehensively studied. Only qualitative data regarding fate and transport in water are available. The half-life of PCNB in the water phase was estimated to be 1.8 days. The two processes reported to be most responsible for the rapid decrease in PCNB concentration in water were volatil ization and sorption to seston and biota, followed by sedimentation as detritus (Schauerte et al., 1982). Neither biodegradation nor photolysis appears to be a significant process for the loss of PCNB from water (Crosby and Hamadmad, 1971; Schauerte et al., 1982). The BCFs for PCNB in the golden orfe, Leucisens idus melanotus, and in rainbow trout, Salmo gairdneri, were reported to be 950- 1130 and 260-590, respectively (Korte et al., 1978; Oliver and Niimi, 1985). It therefore appears that PCNB will moderately bioaccumulate in aquatic organisms. Pertinent data regarding the fate and transport of PCNB in air could not be located in the available literature as cited in the Appendix. Based on its physical properties and its behavior in other media, it would appear that PCNB will persist in the atmo sphere because no known chemical/photochemical processes signif icantly degrade this chemical. Precipitation of particulate PCNB, especially of larger particle size and higher particle density, may remove some PCNB from the atmosphere. PCNB is persistent in soils. The two processes that are important in the loss of PCNB from soils are volatilization and biodegradation; biodegradation is more rapid in soils under anaerobic conditions than under aerobic conditions (Ko and Farley, 1969; Casley, 1968; Gile and Gillett, 1979; Cole and Metcalf, 1977). The average half- life of PCNB in a variety of field soils was reported to be 434 days (Beck and Hansen, 1974). Another study reported the half-lives for PCNB in sandy loam, clay and peaty muck soils as 4.7, 7.6 and 9.7 months, respectively (Wang and Broadbent, 1972). PCNB is expected to be moderately mobile in soils (Gile and Gillett, 1979). Evidence of very restricted (∼ 3% on the average) translocation of PCNB and its metabolites from the roots to foliar tissue in plants was reported by Cairns et al. (1983). Pertinent data regarding the levels of PCNB in ambient and drink ing water could not be located in the available literature as cited in the Appendix. U. S. EPA's STORET database contains 120 entries on the analysis of PCNB in ambient water and aqueous effluent samples. Maximum and minimum PCNB concentrations in these samples were 1.0 and 0.01 μg/l, respectively, with a mean value of 0.4 μg/l. Pertinent data regarding the ambient atmospheric level of PCNB could not be located in the available literature as cited in the Appendix. The concentration of PCNB in the ambient air of a commercial pest control building was reportedly 1.56 μg/m 3 (Yeboah and Kilgore, 1984). In the foods consumed by U.S. adults, infants and toddlers, PCNB residues have been detected mainly in the oils, fats and shortening group of foods (Johnson et al., 1981a,b, 1984a; Johnson and Manske, 1976; Manske and Johnson, 1975; 1984a,b). Occasionally, PCNB has been detected in sugar and adjuncts, fruits and potatoes (Manske and Johnson, 1977; Johnson and Manske, 1977; Podre barac, 1984a). On the basis of the assumption of a maximum PCNB content of 0.006 mg/kg (Johnson et al., 1984a) in oil, fats and shortening composite and a daily adult consumption of 0.070 kg/day of this category of food (Johnson et al., 1984a), the maxi mum daily adult intake of PCNB in the United States has been estimated to be 0.4 μg. The Canadian daily PCNB intake has been reported to vary between 0 and 0.4 μg (McLeod et al., 1980). Little pertinent information is available concerning toxicity of PCNB to aquatic organisms in the available literature. PCNB tox icity to carp increased with increasing temperature, with 24-hour LC 50 values ranging from 40 mg/l at 15° C to 1 mg/l at 35° C (Hashimoto and Nishiuchi, 1981). The lowest concentration at which toxic effects were reported for any species was 1 mg/l. PCNB and its metabolites can apparently accumulate to a signifi cant extent in fish and other aquatic biota. In the species that have been studied, PCNB metabolism involves denitrification but not dechlorination (Bahig et al., 1981; Murphy et al., 1982). Pharmacokinetic and metabolism studies of PCNB indicate that it is rapidly and extensively absorbed from the gastrointestinal tract of rabbits, rats and monkeys (Betts et al., 1955; Korte et al., 1978; Koegel et al., 1979a,b). Following absorption by monkeys and rats, PCNB is rapidly metabolized and the metabolites are widely dis tributed to tissues but do not accumulate (Koegel et al., 1979a,b; Borzelleca et al., 1971). Courtney et al. (1976) demonstrated that PCNB and its metabolites can cross the placental barrier of mice. Major metabolites in urine and feces of monkeys and rats include pentachloroaniline, pentachlorothionanisole, pentachlorobenzene, pentachlorophenol, pentachlorothiophenol and mercapturic acid conjugates (Borzelleca et al., 1971; Koegel et al., 1979c). Metabolic pathways in monkeys involve reduction of the nitro group to pen tachloroaniline and conjugation with glutathione. Conjugation twice with the same molecule of PCNB can lead to bis methylmercapto-tetrachlorobenzene and other tetrachlorometabo lites. Conjugation and nitro reduction combined can lead to tetrachloroaminometabolites. Similar pathways may operate in rats. The metabolites are excreted in the urine and bile. Biliary excretion accounts for the fecal metabolites. Unchanged PCNB was excreted only in the feces of monkeys. The rate of excretion of PCNB and metabolites was dose-dependent: 50% was excreted in 24 hours following a dose of 0.5 mg/kg; and 50% was excreted in 4 days following a dose of 91 mg/kg. There have been five chronic bioassays involving dietary adminis tration of PCNB. BRL (1968a) administered an average concentra tion of 1298 ppm PCNB to 18 male and 18 female B6C3F1 and B6AKF1 mice for 77 weeks. Courtney et al. (1976) later confirmed that the sample was contaminated with 11% hexachlorobenzene (HCB). The only positive neoplastic results were increased inci dences of hepatomas in female B6C3F1 and male B6AKF1 mice (p 99% PCNB, 0.07 ± 0.01% HCB), B6C3F1 mice were given the compound in the diet at 2500 or 5000 ppm for 103 weeks. No evidence of carcinogenicity was found, although high mortality in the treated female mice decreased the sensitivity of the study. Two oral chronic bioassays using technical grade PCNB were per formed in Swiss mice (Van der Heijden and Til, 1974) and albino rats (Anonymous, n.d.). The compound was administered for 80 weeks (mice) and 104 weeks (rats), at 0, 100, 400 or 1200 ppm. In high-dose female mice there were increased (p 12 g/kg. The technical grade material has been found to be more hazardous than the wettable powder (Finnegan et al., 1958; Renner, 1980; Cholakis et al., 1981). Schumann and Borzelleca (1978) reported methmoglobinemia in rats after oral administration of PCNB, an effect not observed by Koegel et al. (1979b) in rhesus monkeys. Dose and species differences were the two most likely reasons for these discrepancies. Although the evidence indicates that relatively pure PCNB (< 1% HCB) did not induce hepatomas in B6C3F1 mice (NCI, 1978; NTP, 1986), albino Swiss female mice fed relatively pure PCNB with HCB contamination of 2.7% developed statistically significant increased incidences of subcutaneous fibromas and fibrosarcomas. From these data a q1* for humans of 3.93 × 10 -2 (mg/kg/day) -1 was derived. Another bioassay with 11% HCB contamination shows a hepatoma response in male B6AKF1 and female B6C3F1 mice. These data were used to derive a human qi* of 0.26 (mg/kg/day) -1 . Since the potency of the tested PCNB compounds seems related at least in part to the level of HCB contaminant, any statements about risk levels derived from the available data must be referenced to the purity of PCNB. Arbitrarily, the bioassay with the highest level of PCNB contamination will be used to derive drinking water levels and RQ "F" factors. The concentrations in water associated with risk levels of 10 -5 , 10 -6 and 10 -7 are 1.33 × 10 -3 , 1.33 × 10 -4 and 1.33 × 16 -5 mg/l. An F factor of 1.4 (mg/kg/day) -1 was also derived. The limited evidence in animals and lack of evidence in humans indicate that PCNB is an EPA Group C chemical. Therefore, PCNB has a LOW hazard ranking under CERCLA. At 180 ppm (2.7 mg/kg/day), dogs had choles tatic hepatosis and bile nephrosis. An RQ of 1000 was also derived based on the liver pathology in dogs at 180 ppm in the study by Borzelleca et al. (1971).

Abstract:DIOXIN TOXIC EQUIVALENCY FACTOR EVALUATION OVERVIEW: Polyhalogenated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) have the ability to bind to and activate the ligand-activated transcription factor, the aryl hydrocarbon receptor (AhR). Structurally related compounds that bind to the AhR and exhibit biological actions similar to TCDD are commonly referred to as "dioxin-like compounds" (DLCs). Ambient human exposure to DLCs occurs through the ingestion of foods containing residues of DLCs that bio-concentrate through the food chain. Due to their lipophilicity and persistence, once internalized they accumulate in body tissues, mainly adipose, resulting in chronic lifetime human exposure. Since human exposure to DLCs always occurs as a complex mixture, the toxic equivalency factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds. The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, the most potent congener. This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals, based on a common mechanism of action involving an initial binding of DLCs to the AhR. The toxic equivalency of DLCs was nominated for evaluation because of the widespread human exposure to DLCs and the lack of data on the adequacy of the TEF methodology for predicting relative potency for cancer risk. To address this, the National Toxicology Program conducted a series of 2-year bioassays in female Harlan Sprague-Dawley rats to evaluate the chronic toxicity and carcinogenicity of DLCs and structurally related polychlorinated biphenyls (PCBs) and mixtures of these compounds. 2-YEAR STUDY: The 2-year study of a binary mixture of PCB 126 and PCB 153 was designed to assess the carcinogenicity of a constant ratio mixture of PCB 126 and PCB 153. In addition, varying ratio mixture groups were used to assess the impact of increasing PCB 153 on the carcinogenicity of PCB 126. Dose groups were divided into two study arms (Figure 1). TCDD equivalent (TEQ) doses are based on the PCB 126 doses after adjustment for the PCB 126 TEF of 0.1. Groups of 81 (Groups 2, 3, 5, and 7) or 80 (Groups 4 and 6) female rats received a mixture of PCB 126 and PCB 153 in corn oil:acetone (99:1) by gavage 5 days per week for up to 105 weeks; a group of 81 female rats received the corn oil:acetone (99:1) vehicle only and served as the vehicle control (Group 1). Up to 10 rats per group were evaluated at 14, 31, and 53 weeks. Survival of all dosed groups was similar to that of the vehicle controls. The mean body weights of Groups 4 and 5 were generally less than those of the vehicle controls after week 25. The mean body weights of Group 6 were less after week 12, and those of Group 7 were less after week 8. Thyroid Hormone Concentrations: Alterations in serum thyroid hormone levels were evaluated at the 14-, 31-, and 53-week interim evaluations. In the constant ratio groups, serum total thyroxine (T(4)) and free T(4) generally showed a treatment-related decrease relative to controls. Serum total triiodothyronine (T(3)) exhibited a treatment-related increase at the 14-, 31-, and 53-week interim evaluations, but serum thyroid stimulating hormone (TSH) levels were increased at the 14-week time point only. In the varying ratio groups, the decrease in total and free T(4) was more pronounced in those groups dosed with the increasing proportion of PCB 153 at the 31- and 53-week time points. Hepatic Cell Proliferation Data: To evaluate hepatocyte replication, analysis of labeling of replicating hepatocytes with 5-bromo-2'-deoxyuridine was conducted at the 14-, 31-, and 53-week interim evaluations. At 31 and 53 weeks, a significant increase in the hepatocellular labeling index occurred in Group 7. In the varying ratio groups, the labeling index at the 53-week interim time point was significantly higher in Group 6, which had the highest proportion of PCB 153 compared to the other varying ratio groups. Cytochrome P450 Enzyme Activities: To evaluate the expression of known PCB 126-responsive genes, CYP1A1-associated 7-ethoxyresorufin-O-deethylase (EROD) and CYP1A2-associated acetanilide-4-hydroxylase (A4H) activities were evaluated at the 14-, 31-, and 53-week interim evaluations. In addition, PCB 153-inducible CYP2B-associated 7-pent-oxyresorufin-O-dealkylase (PROD) activity was analyzed. In the constant ratio Groups 2, 3, 5, and 7, hepatic and pulmonary EROD (CYP1A1) activities, hepatic A4H (CYP1A2) activities, and hepatic PROD (CYP2B) activities were significantly greater in all dosed groups compared to the vehicle controls at weeks 14, 31, and 53. In the varying ratio groups, hepatic EROD, A4H, and PROD activities at 14 weeks were higher in groups receiving a greater proportion of PCB 153 in the PCB mixture. At 31 and 53 weeks, hepatic CYP1A1 and CYP1A2 enzyme activities in Group 6 were generally lower than in Groups 4 and 5. Determinations of PCB 126 and PCB 153 Concentrations in Tissues: Concentrations of PCB 126 and PCB 153 were determined in fat, liver, lung, and blood at the 14-, 31-, and 53-week interim evaluations and at the end of the 2-year study (105 weeks). PCB 126 was not detectable in vehicle control animals, but increased with increasing dose of PCB 126 and duration of exposure; the highest concentrations were found in liver and fat, and lower levels were seen in lung and blood. Increasing the proportion of PCB 153 in the mixture relative to PCB 126 led to a general decrease in the amount of PCB 126 in liver and lung at the later time points, whereas in fat and blood, there was generally either no effect of PCB 153 on the disposition of PCB 126, or there was an increase in the amount of PCB 126 in the tissue. In vehicle control animals, PCB 153 was detectable in the fat at all time points, in the lung at all time points except 53 weeks, and in the liver and blood at 2 years. PCB 153 was measurable in all examined tissues of treated animals, with the highest concentrations found in fat at the end of the 2-year study in groups administered the highest doses of PCB 153. Pathology and Statistical Analyses -- Constant Ratio Mixture of PCB 126 and PCB 153: At 14, 31, and 53 weeks, the absolute and relative liver weights of all dosed groups were generally greater than those of the vehicle controls. Exposure to the PCB mixture led to significant toxicity in the liver. At 14 weeks, the incidences of several nonneoplastic liver lesions were increased compared to the vehicle controls including hepatocyte hypertrophy, pigmentation, multinucleated hepatocytes, and diffuse fatty change. The spectrum and severity of effects increased with dose and duration of exposure. At the end of the 2-year study, there were significantly increased incidences and severities of toxic hepatopathy characterized by hepatocyte hypertrophy, multinucleated hepatocytes, pigmentation, diffuse and focal fatty change, eosinophilic focus, nodular hyperplasia, cholangiofibrosis, oval cell hyperplasia, bile duct cysts, bile duct hyperplasia, necrosis, and portal fibrosis. Significantly increased incidences of hepatocellular adenoma, cholangiocarcinoma, and hepatocholangioma were observed in the study. In addition, two animals in the highest dose group had hepatocellular carcinoma. The incidences of these lesions generally exceeded the historical vehicle control ranges. At 2 years, a significantly increased incidence of cystic keratinizing epithelioma of the lung was observed in Group 7. In addition, single occurrences of squamous cell carcinoma were seen in the top two dose groups. Nonneoplastic effects whose incidences were increased in the lung included bronchiolar metaplasia of the alveolar epithelium and squamous metaplasia. Significantly increased incidences of squamous cell carcinoma (gingival) of the oral mucosa were seen at the end of the 2-year study and were accompanied by increased incidences of gingival squamous hyperplasia. In the pancreas at 53 weeks, the incidence of acinar cytoplasmic vacuolization was significantly increased in the highest dose group. At 2 years, increased incidences of acinar atrophy and acinar cytoplasmic vacuolization were seen in addition to pancreatic acinar neoplasms in dosed groups. In Groups 5 and 7, these incidences exceeded the historical vehicle control ranges. In the uterus at 2 years, there was a marginal increase in the incidence of squamous cell carcinoma in Group 5. Numerous nonneoplastic effects were seen in other organs at the interim time points including atrophy of the thymus and follicular cell hypertrophy of the thyroid gland. These responses were also affected by administration of the mixture of PCB 126 and PCB 153 at the end of the 2-year study and were accompanied by additional nonneoplastic responses in numerous organs including atrophy of the adrenal cortex and cortical hyperplasia, severity of nephropathy, and incidences of pigmentation of the kidney. Other nonneoplastic lesions that were treatment related were forestomach hyperplasia, hyperplasia of the nasal respiratory epithelium, metaplasia of the olfactory epithelium, and ectasia of the mandibular lymph node. Varying Ratio Mixture of PCB 126 and PCB 153: An effect of increasing the proportion of PCB 153 in the PCB mixture was seen in several tissues, most notably in the liver. Treatment-related nonneoplastic effects seen across the varying ratio groups were generally the same as those seen in the constant ratio groups. In general there was a positive effect of PCB 153 in the mixture on the incidences and severities of these lesions with higher incidences and higher severities being seen in Group 6, which had the highest proportion of PCB 153. (ABSTRACT TRUNCATED).

Health and Environmental Effects Profile for Pentachloronitrobenzene

Effects of Pentachlorophenol on the Detoxification System in White-Rumped Munia (lonchura Striata).

Toxicology and carcinogenesis studies of 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (CAS No. 31508-00-6) in female harlan Sprague-Dawley rats (gavage studies)

Pentachlorophenol causes redox imbalance, inhibition of brush border membrane and metabolic enzymes, DNA damage and histological alterations in rat kidney

Polychlorinated naphthalenes in U.K. soils: time trends, markers of source, and equilibrium status

Unintentional Formed PCDDs, PCDFs, and DL-PCBs As Impurities in Chinese Pentachloronitrobenzene Products

Pentachlorophenol Exposure Induced Neurotoxicity by Disrupting Citrulline Metabolism in Larvae and Adult Zebrafish.

Several Current-Use, Non-Pbde Brominated Flame Retardants Are Highly Bioaccumulative: Evidence from Field Determined Bioaccumulation Factors.

Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (gavage studies)

Β-Cypermethrin and Its Metabolite 3-Phenoxybenzoic Acid Exhibit Immunotoxicity in Murine Macrophages.

3,3′-Dichlorobiphenyl Is Metabolized to a Complex Mixture of Oxidative Metabolites, Including Novel Methoxylated Metabolites, by HepG2 Cells

Polychlorinated biphenyls in a grassland food network: Concentrations, biomagnification, and transmission of toxicity

Bioaccumulation and degradation of pentachloronitrobenzene in Medicago sativa

NTP technical report on the toxicity studies of a Chemical Mixture of 25 Groundwater Contaminants Administered in Drinking Water to F344/N Rats and B6C3F(1) Mice

Genetoxicity of Sodium Pentachlorophenate(Na-PCP)

Global Trends And Diversity In Pentachlorophenol Levels In The Environment And In Humans: A Meta-Analysis

Isolation and Characterization of PCNB Degrading Bacterium, Pseudomonas aeruginosa Strain I-41

Toxicology studies of a pentabromodiphenyl ether mixture [DE-71 (technical grade)] in F344/N rats and B6C3F1/N mice and toxicology and carcinogenesis studies of a pentabromodiphenyl ether mixture [DE-71 (technical grade)] in Wistar Han [Crl:WI(Han)] rats and B6C3F1/N mice (gavage studies)

Absence of plant uptake and translocation of polybrominated biphenyls (PBBs)

Bioaccumulation, Trophic Transfer, and Biotransformation of Polychlorinated Diphenyl Ethers in a Simulated Aquatic Food Chain

Carcinogenic activity of pentabrominated diphenyl ether mixture (DE-71) in rats and mice